Although it has been posited that the proximity of the substituted polar amino acid to the poly(A) signal may be affect XPD protein function (Dybdahl et al, 1999), the molecular mechanism by which this polymorphism alters the efficacy of oxaliplatin in tumour cells remains unknown. This evidence concerns the gene ERCC2 and neoplasm.